Composite extract and application thereof in medicine for removing scars

Abstract

The invention discloses a compound extract of henbane leaf and panax japonicus, a preparation method of the compound extract and application of the compound extract in scar removing medicine, and the compound extract for treating scars is characterized in that the compound extract is formed by mixing a henbane leaf extract and a panax japonicus extract; wherein the henbane leaf extract is prepared by mixing and crushing henbane leaves and chalcanthite, adding an ammonia water ethanol solution for extraction, adding vegetable oil, heating and mixing, volatilizing to remove ammonia gas, filtering to remove filter residues, and collecting an oily extract, namely the henbane leaf extract; the panax japonicus extract is prepared by crushing panax japonicus, adding water, decocting, extracting, concentrating and drying into powder. The compound extract can effectively remove scars formed by tissue hyperplasia and has no side effect.

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and in particular relates to a composite extract and application thereof in scar removing medicines. Background Art

[0002] Scars are the product of wound healing, among which hypertrophic scars (HS) are the most common. The formation of HS usually includes three steps: inflammation, proliferation, and remodeling. When the dermis is damaged, there will be a 2-3 day hemostasis and inflammation period, followed by a proliferation period, during which fibroblasts are activated, proliferate and differentiate in large quantities, and some cells differentiate into myofibroblasts. Myofibroblasts have stronger contractility and accelerate wound healing. In normal conditions and injuries, myofibroblasts age, apoptose, or form inactive fibroblasts, and the extracellular matrix (ECM) is synthesized, decomposed, and remodeled. Excessive proliferation of fibroblasts and incomplete decomposition of ECM can lead to HS. Moreover, type I collagen (Col I) and type III collagen (Col III), as the main components of ECM, are continuously synthesized and deposited during the occurrence and development of HS.

[0003] According to traditional Chinese medicine, HS is a stasis syndrome, and its causes are related to congenital factors or injuries caused by metal knives, burns caused by water or fire, residual toxins not completely eliminated, and invasion of the skin by exogenous pathogens, which cause stagnation of qi and blood, obstruction of meridians, and damp-heat stagnation. The five flavors of Chinese medicine refer to the five flavors of pungent, sweet, sour, bitter, and salty. Different flavors have different effects, such as the belonging and efficacy connotations of the five different flavors of "pungent and dispersing, sweet and slow, sour and astringent, bitter and firm, and salty and soft". Traditional Chinese medicine believes that the treatment of HS is mainly based on regulating qi and activating blood circulation, softening and dispersing nodules, and removing dampness and removing blood stasis, which corresponds to the "pungent, salty, and bitter" among the five flavors of Chinese medicine.

[0004] Every year, a large number of people are left with scars due to surgery or trauma. Although scars do not directly affect people's health, and most patients will not seek treatment for scars, the existence of scars will cause other problems, such as functional disorders, causing great physical and mental obstacles. At present, the treatment of scars is mainly pressure therapy, drug therapy, surgical treatment or medical beauty measures to remove scars, but the treatment cost is high and the effect is often unsatisfactory. Therefore, it is very important to choose new and effective treatment methods for scars. Summary of the invention

[0005] The invention provides a Chinese medicine composition and a preparation method thereof and application of the Chinese medicine composition in scar removal medicine, which can effectively remove scars formed by tissue hyperplasia and has no side effects.

[0006] The technical scheme of the present invention is to provide a composite extract for treating scars, wherein the composite extract is prepared by mixing a scopolamine leaf extract and a panax notoginseng extract; wherein the scopolamine leaf extract is prepared by mixing and crushing scopolamine leaves and gallstones, adding an ammonia ethanol solution for extraction, then adding vegetable oil for heating and mixing, volatilizing to remove ammonia, filtering to remove filter residues, and collecting an oily extract to obtain the scopolamine leaf extract; and the panax notoginseng extract is prepared by crushing the panax notoginseng, adding water for decoction, and then concentrating and drying into powder.

[0007] Furthermore, by weight, when preparing the Scopolamine leaf extract, the Scopolamine leaf is 8-12 parts and the gallstones are 3-9 parts; when preparing the Panax japonicus extract, the Panax japonicus is 6-10 parts.

[0008] Furthermore, the ammonia ethanol solution is an ethanol solution with an ammonia volume percentage concentration of 20%; the amount of the ammonia ethanol solution added is 0.8 to 1.2 times the mass of scopolamine leaves and gallstones; and the extraction time is 18 to 30 hours.

[0009] Furthermore, the vegetable oil is peanut oil, and the added amount is 8 to 12 times the sum of the mass of scopolamine leaves and gallstones; the vegetable oil is preheated to 60 to 70° C. before being added, and the heating temperature is 65° C. after being added.

[0010] Furthermore, when preparing the Panax japonicus extract, it is boiled and extracted for multiple times with water, the decoction extracts are combined and concentrated under reduced pressure, and finally spray-dried to obtain the extract.

[0011] The invention also relates to the application of the composite extract in preparing a scar removing medicine.

[0012] The invention also relates to a medicine for removing scars, wherein the effective component of the medicine is the composite extract.

[0013] Furthermore, the drug also includes pharmaceutically acceptable excipients.

[0014] Furthermore, the dosage form is a cream, an ointment, a gel, a liniment or a patch.

[0015] The present invention has the following beneficial effects: The composite extract provided by the present invention adopts traditional medicinal materials, such as scopolamine leaves, gallstones and bamboo joints, wherein scopolamine leaves are dry leaves of the genus Hyoscyamus of the Solanaceae family, with a slightly smelly smell, bitter and slightly pungent taste, and can be used to treat carbuncle, swelling and toxicity and toothache, gallstones are crystals of gallstones of the sulfate gallstone family mineral gallstones, and have the effects of vomiting, detoxification and decoration, and are mainly used to treat stroke, epilepsy, laryngeal paralysis, laryngeal wind, phlegm congestion, dental caries, mouth sores, rotten string wind eyes, hemorrhoids, swelling and toxicity. External use can be combined with protein to generate insoluble protein compounds and precipitate, thereby removing rot and regenerating muscles. Bamboo joints are the dried rhizomes of the bamboo joints of the Araliaceae plant, which have the effects of dispersing blood stasis, stopping bleeding, reducing swelling, removing phlegm, relieving cough, etc. Modern pharmacological studies have shown that it has strong antioxidant, anti-inflammatory and tissue repair effects. The present invention can completely soften keloids by combining the three, thereby effectively removing scars. Experimental results show that after 7 days of application and administration of the high concentration (0.6 g / g) of the composite extract, the medium concentration (0.5 g / g) of the composite extract, and the low concentration (0.4 g / g) of the composite extract, the color of the scar changes from obvious congestion to slightly lighter, the surrounding inflammatory reaction is weakened, and the redness, swelling, heat and pain reactions are alleviated; after 14 days of application and administration, the inflammatory reaction is more obviously weakened, and the redness, swelling, heat and pain reactions gradually disappear; after 21 days of application and administration, the scar skin has returned to a normal skin state, the scar deposition is reduced, the scar tissue is thinner, and the composite extract has no effect on the main organ indexes and body weight of the model rats, indicating that the composite extract can effectively remove scars without side effects.

[0016] The present invention also studies the mechanism of action of the composite extract, which can effectively remove scar tissue. The mechanism of action is related to the inhibition of the JAK2 / STAT3 signaling pathway, which leads to the inhibition of VEGFR1 activity, thereby reducing angiogenesis and playing a role in scar repair. Animal experiments show that compared with the normal group, there is no significant difference in the organ indexes of SD rats used in different dosage groups (P>0.05). This shows that the composite extract can effectively remove scars without the side effect of organ damage. The proposal of the present invention provides a new and effective technical means for the treatment of scars, which can produce huge economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The effect of the composite extract in Example 4 on the body weight of experimental rats.

[0018] Figure 2 The effect of the composite extract in Example 4 on the appearance of hypertrophic scars on the skin of experimental rats.

[0019] Figure 3 This is the H&E staining analysis of Example 4 showing the effect of the composite extract on the morphology of hypertrophic scar tissue in experimental rat skin.

[0020] Figure 4This is the MASSON staining analysis of the effect of the composite extract on the morphology of hypertrophic scar tissue in experimental rat skin in Example 4.

[0021] Figure 5 This is the Sirius red staining analysis of the effect of the composite extract on the morphology of hypertrophic scar tissue in experimental rat skin in Example 4. DETAILED DESCRIPTION

[0022] The present invention is described in detail below in conjunction with specific embodiments. This embodiment is implemented based on the technical solution of the present invention, and provides a detailed implementation method and a specific operation process, but the protection scope of the present invention is not limited to the following embodiments.

[0023] Example 1 Preparation of a composite extract for treating scars (1) Weigh each raw material by weight, mix 10 parts of Scopolia scopolamita leaves and 6 parts of gallstones and grind them into coarse powder, add 0.8 times the weight of the drug in 20% ammonia ethanol solution, soak for 24 hours, add peanut oil preheated to 60-70°C, heat and stir in a water bath to evaporate the ammonia, filter to remove the solid residue, and collect the green oily liquid (I).

[0024] (2) Weigh 8 parts of Panax notoginseng according to the above weight proportions, grind into coarse powder, add 10 times the amount of water, decoct and extract twice, each time for 1 hour, concentrate under reduced pressure, and spray dry to obtain Panax notoginseng dry powder (II).

[0025] (3) Add the dried Panax notoginseng extract powder (II) to the green oily extract (I), mix well, and obtain a composite extract.

[0026] Example 2 Preparation of a composite extract for treating scars (1) Weigh each raw material by weight, mix 8 parts of Scopolia scopolamita leaves and 3 parts of gallstones and grind them into coarse powder, add 20% ammonia ethanol solution in an amount of 1.0 times the weight of the drug, soak for 24 hours, add peanut oil preheated to 60-70°C, heat and stir in a water bath to evaporate the ammonia, filter to remove the solid residue, and collect the green oily liquid (I).

[0027] (2) Weigh 6 parts of Panax notoginseng according to the above weight proportions, grind into coarse powder, add 10 times the amount of water, decoct and extract twice, each time for 1 hour, concentrate under reduced pressure, and spray dry to obtain Panax notoginseng dry powder (II).

[0028] (3) Add the dried Panax notoginseng extract powder (II) to the green oily extract (I), mix well, and obtain a composite extract.

[0029] Example 3 Preparation of composite extract for removing scars (1) Weigh the following raw materials according to their weight: 12 parts of Scopolia scopolamita leaves and 9 parts of gallstones are mixed and ground into coarse powder. 0.6 times the weight of the drug is added with 20% ammonia ethanol solution, and the mixture is soaked for 24 hours. Peanut oil preheated to 60-70°C is added, and the mixture is heated and stirred in a water bath to evaporate the ammonia. The mixture is filtered to remove the solid residue and the oily liquid (I) is collected.

[0030] (2) Weigh 10 parts of Panax notoginseng according to the above weight proportions, grind into coarse powder, add 10 times the amount of water, decoct and extract twice, each time for 1 hour, concentrate under reduced pressure, and spray dry to obtain Panax notoginseng dry powder (II).

[0031] (3) Add the dried Panax notoginseng extract powder (II) to the green oily extract (I), mix well, and obtain a composite extract.

[0032] Example 4 Application of the composite extract in the treatment of scars 1 Experimental Materials 1.1 Drugs and Animals The composite extract was prepared from Scopolia scopolamita, Gastrodia elata, and Panax japonicus. Scar antipruritic ointment was purchased from Sichuan Defeng Pharmaceutical Co., Ltd. and is an ointment for the treatment of scars. 102 adult healthy SD rats, with an initial body weight of 200±20g, were provided by the Experimental Animal Center of Hubei Three Gorges University, license number: CTGUAEWC-2021-085. The rats were placed under 12-h day and night alternating lighting, and food and water were freely available.

[0033] 1.2 Instruments and reagents Low-temperature high-speed centrifuge (5415D, Eppendorf, Germany); enzyme-linked immunosorbent assay (infiniteM200PRO, TECAN, Switzerland); embedding machine (1150H, Leica, Germany); ultrathin slicer (ULTRACUTR, Leica, Austria); H&E stainer (Shenzhen Dakoway Medical Technology Co., Ltd.); slice baking machine (YD-AB, Jinhua Yidi Medical Equipment Co., Ltd.); Ecopure ultrapure water system (Ecopure International, USA); RIPA lysis buffer (Beijing Solarbio Technology Co., Ltd.); MASSON staining kit (Beijing Solarbio Technology Co., Ltd.); Sirius red staining kit (Beijing Solarbio Technology Co., Ltd.); BCA protein concentration determination kit (Nanjing Biyuntian Biotechnology Research Institute); pre-stained rainbow protein marker (Thermo Fisher Scientific, USA); ethanol (Tianjin Komeiou Chemical Reagent Co., Ltd.); ammonia water (Tianjin Komeiou Chemical Reagent Co., Ltd.).

[0034] 2 Experimental methods 2.1 Preparation of composite extracts The composite extract was prepared according to the method of Example 1.

[0035] 2.2 Establishment of animal model SD rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg / kg). After confirming that the anesthesia was effective, the skin of the rat's tail was cleaned and disinfected once with alcohol and three times with iodine according to surgical routine. On the dorsal side of the rat's tail, 3 cm away from the base of the tail, a 1×2 cm square incision was made with a scalpel and ophthalmic scissors using methylene blue as a mark. The entire layer of skin and the fascia were completely removed. After the wound hemostasis, the wound was covered with sterile dry gauze and bandaged. After the operation was completed and the wound was formed, mechanical stress was applied to the wound to promote the formation of a tension hypertrophic scar, such as Figure 1 As shown. A pre-customized stainless steel metal ring with a diameter of 2 cm was fixed on the opposite side of the rat tail wound (ventral side of the rat tail) facing the wound. The rat tail was bent along the diameter of the metal ring and fixed to the metal ring with a binding tape, so that the wound was subjected to continuous and stable tension. The fixed rat tail was bandaged well, the metal ring was continuously worn, the gauze of the wound was changed every other day, and the healing and scar formation were observed and recorded. The scab fell off and a hypertrophic scar was formed, which was recorded as 0 days.

[0036] 2.3 Experimental Grouping After successful modeling, the mice were randomly divided into groups according to body weight: (1) model group, (2) low-dose group (active ingredient 40%), (3) medium-dose group (active ingredient 50%), (4) high-dose group (active ingredient 60%), (5) positive drug group (scar antipruritic ointment), and (6) blank group without any treatment; 6 mice in each group were fed with ordinary feed and had unlimited water. The drug was administered 3 times a day, 0.2 g / time, and applied evenly. The positive drug group and the experimental group were treated in the same way.

[0037] 2.4 Recording changes in body weight and food intake After modeling, the mice were randomly divided into groups and their activities were observed every day, and their body weight changes and food intake were recorded.

[0038] 2.5 Detection of inflammatory factors in blood The experimental mice were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg / kg), and blood samples were collected from the abdominal aorta. The blood samples were kept at room temperature for 1 h and then centrifuged (2000 rpm, 15 min) to separate the serum for detection of inflammatory factor content, pro-inflammatory factors (PGE2, IL-6, IL-8, IL-1β, IL-18, TNF-α, COX-2, TGF-β1, TGF-β2) and anti-inflammatory factors (TGF-β3, IL-4, IL-10, COX-1) and other indicators.

[0039] 2.6 Organ index detection The rats were weighed before being killed, and the liver, heart, kidney, spleen, and lungs were taken out and washed with pre-cooled PBS. The excess liquid was then absorbed with filter paper. The weight of each tissue was weighed and the organ index was calculated according to the formula: organ index (%) = organ weight (g) / body weight (g) × 100%.

[0040] 2.7 Recording the recovery of hypertrophic scars after drug administration Photographs were taken at 0 d, 7 d, 14 d, and 21 d to record scar recovery. The photos were taken with a Canon 600D under the same light source, focal length, and distance.

[0041] 2.8 Detection of extracellular matrix (ECM) in skin scar tissue Scar tissues were collected on 0 d, 7 d, 14 d, and 21 d, and the expression of Col Ⅰ, Col Ⅲ, and VEGFR1 proteins was verified by Western-blot method.

[0042] Protein was extracted according to the instructions of the protein extraction kit: scar tissue was weighed on ice, lysis solution (0.1 g / 1 mL, lysis solution preparation: lysis stock solution: phosphatase inhibitor: PMSF = 100:1:1) was added according to the volume ratio, homogenized and ground at 4°C for 10 min, placed on ice for lysis for 30 min, and then centrifuged at 4°C (12000 rpm, 10 min), the upper layer of tissue lysis solution was taken into a new pre-cooled EP tube, and the volume was recorded for protein quantification.

[0043] Protein quantification: Use the BCA kit to quantify the protein samples. Prepare the BCA assay solution according to the ratio of A solution: B solution = 50:1 in the kit instructions. Select a group of empty wells in the 96-well plate according to the number of samples, add 19 µL PBS solution to each well, then pipette 1 µL of the protein sample solution to be tested and add it to the PBS solution. After adding 200 µL BCA assay solution to each well, oscillate at 500 rpm on an oscillator for 1 min to fully mix it, and then place it in a 37 ℃ drying oven for 30 min. After the reaction is completed, measure the absorbance value at a wavelength of 562 nm. After calculating the protein sample concentration based on the standard curve of the kit, add 5 × buffer and ultrapure water according to the calculated amount to adjust the protein concentration to a uniform set concentration, mix by pipetting, and boil in boiling water for 10 min to denature it, centrifuge, vortex mix, and then dispense it and store it in an ultra-low temperature storage box.

[0044] 10% polyacrylamide gel was electrophoresed at 80 V and 28 mA for 2.5 h. The membrane was transferred to PVDF membrane at 200 mA for 2 h. The membrane was blocked with 5% skim milk, and the corresponding primary antibodies were added dropwise at 4°C overnight. The membrane was rinsed with TBST containing 0.1% Tween 20 for 10 min×3 times, and then the secondary antibody labeled with horseradish peroxidase was added and incubated at room temperature for 1.5 h. The membrane was rinsed with 0.1% TBST for 10 min×3 times. The membrane was detected by ECL luminescence and developed by a developer. The image was scanned and the gray value of each band was measured. After standardization with β-actin as the internal control, the changes in the expression of Col Ⅰ, Col Ⅲ, and VEGFR1 proteins were compared.

[0045] 2.9 Detection of proteins related to the IL-6 / JAK2 / STAT3 pathway in skin scar tissue Western blot was used to detect the expression levels of IL-6, JAK2, P-JAK2, STAT3, and P-STAT3 proteins.

[0046] 3 Results and analysis 3.1 Effects of compound extracts on body weight and food intake of experimental rats Results: There was no significant difference in weight gain and food intake among the experimental mice in each group (P>0.05). Figure 1 , the difference in food intake is shown in the table below.

[0047] Table 1. Effects of the compound extract on food intake of 21-day experimental mice ( ±S, n = 6)

[0048] 3.2 Effects of compound extracts on organ indexes of experimental rats The index of each organ was calculated, and the results are shown in the table below. Compared with the normal group, there was no significant difference in the index of each organ of the SD rats used in each experimental group (P>0.05). The experiment showed that the cream had no side effects of organ damage.

[0049] Table 2. Effects of compound extracts on organ indexes of experimental rats ( ±S, n = 6)

[0050] 3.3 Effects of the compound extract on pro-inflammatory and anti-inflammatory factors in the serum of experimental rats The results are shown in the table below. Compared with the blank group, the levels of pro-inflammatory factors such as PGE2, IL-8, IL-6, IL-1β, IL-18, TNF-α, COX-2, TGF-β1 and TGF-β2 in the serum of rats in the Model group were significantly increased, and the levels of anti-inflammatory factors such as TGF-β3, IL-4, IL-10 and COX-1 were significantly decreased (P<0.05). After treatment with the composite extract, the above-mentioned pro-inflammatory factor indicators were significantly decreased (P<0.05), and the levels of anti-inflammatory factors were significantly increased (P<0.05).

[0051] Table 3. Effects of the compound extract on anti-inflammatory factors in the serum of experimental rats ( ±S, n = 6)

[0052] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0053] Table 4. Effects of the compound extract on pro-inflammatory factors in the serum of experimental rats ( ±S, n = 6)

[0054] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0055] 3.4 Effects of the compound extract on the appearance and histomorphology of hypertrophic scars in experimental rats 3.4.1 Effect of the compound extract on the appearance of hypertrophic scars in experimental rats In terms of appearance, at 0 days, the hypertrophic scars protruded from the skin surface, with irregular shapes, uneven heights, firm texture, dark red color, and obvious congestion; after 7 days of application of the composite extract, the color changed from obvious congestion to slightly lighter, the surrounding inflammatory reaction weakened, and the redness, swelling, heat and pain reactions were alleviated; after 14 days of application, the inflammatory reaction weakened more significantly, and the redness, swelling, heat and pain reactions gradually disappeared; after 21 days of application, the scar skin had returned to normal skin state, with less scar deposition and thinner scar tissue. Results See Figure 2 .

[0056] 3.4.2 Effect of the compound extract on the morphology of hypertrophic scar tissue in experimental rat skin H&E staining analysis of the effects of the compound extract on the morphology of hypertrophic scar tissue in experimental rats Compared with the blank group, the Model group had an increased inflammatory response, a large number of inflammatory cells, capillary hyperplasia, obvious dermal hyperplasia, a significant increase in the number of fibroblasts, and the disappearance of skin appendages such as sebaceous glands, sweat glands, and hair follicles, which was consistent with the pathological characteristics of hyperplastic scar tissue; after applying the fat-soluble extract of Scopolia scopolia leaves, the dermal hyperplasia in different dosage groups was significantly reduced, almost returning to normal skin state. The results are shown in Figure 3 .

[0057] Masson staining analysis of the effects of the compound extract on the morphology of hypertrophic scar tissue in experimental rats Compared with normal skin tissue, a large number of blue-stained collagen fibers can be seen in hypertrophic scar tissue, and their arrangement is disordered; after applying and administering the drug at different times, the collagen fibers are reduced to varying degrees. The results are shown in Figure 4 .

[0058] Sirius red staining analysis of the effects of the compound extract on the morphology of hypertrophic scar tissue in experimental rats At 0 days, compared with normal skin tissue, the area of ​​type I collagen and type III collagen in hypertrophic scar tissue increased significantly; after different time periods of application, the collagen fibers decreased to varying degrees. The results are shown in Figure 5 .

[0059] 3.5 Study on the mechanism of compound extracts in treating scars 3.5.1 Effect of the compound extract on IL-6 expression in rat tail scar tissue Compared with the blank group, the expression of IL-6 protein in the model group was significantly increased, and the expression was significantly reduced after administration, and the low, medium and high doses were all significantly reduced (P < 0.05). The results are shown in the table below.

[0060] Table 5. Effect of compound extract on IL-6 expression in rat tail scar tissue

[0061] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0062] 3.5.2 Effect of the compound extract on JAK2 expression in rat tail scar tissue Compared with the blank group, the expression of JAK2 protein in the model group and the drug-treated group was significantly increased (P < 0.05). The results are shown in the table below.

[0063] Table 6. Effects of the compound extract on JAK2 expression in rat tail scar tissue

[0064] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0065] 3.5.3 Effect of the compound extract on the expression of P-JAK2 in the tail scar tissue of experimental rats Compared with the blank group, the expression of P-JAK2 protein in the model group was significantly increased, and the expression was significantly reduced after administration, and the low, medium and high doses were all significantly reduced (P < 0.05). The results are shown in the table below.

[0066] Table 7. Effect of compound extract on P-JAK2 expression in rat tail scar tissue

[0067] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0068] 3.5.4 Effect of the compound extract on STAT3 expression in rat tail scar tissue Compared with the blank group, the expression of STAT3 protein in the model group and the drug-treated group was significantly increased (P < 0.05). The results are shown in the table below.

[0069] Table 8 Effect of compound extract on STAT3 expression in rat tail scar tissue

[0070] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0071] 3.5.5 Effect of the compound extract on the expression of P-STAT3 in the tail scar tissue of experimental rats Compared with the blank group, the expression of P-STAT3 protein in the model group was significantly increased, and the expression was significantly reduced after administration, and the low, medium and high doses were all significantly reduced (P < 0.05). The results are shown in the table below.

[0072] Table 9. Effect of compound extract on P-STAT3 expression in rat tail scar tissue

[0073] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0074] 3.5.6 Effect of the compound extract on the expression of VEGFA in the tail scar tissue of experimental rats Compared with the blank group, the expression of VEGFA protein in the model group was significantly increased, and the expression was significantly reduced after administration, and the low, medium and high doses were all significantly reduced (P < 0.05). The results are shown in the table below.

[0075] Table 10. Effect of compound extract on VEGFA expression in rat tail scar tissue

[0076] Note: Compared with the Control group, # P <0.05,## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0077] 3.5.7 Effect of the compound extract on the expression of VEGFR1 in rat tail scar tissue Compared with the blank group, the expression of VEGFR1 protein in the model group was significantly increased, and the expression was significantly reduced after administration, and the expression was significantly reduced at low, medium and high doses ( P <0.05), the results are shown in the table below.

[0078] Table 11. Effect of the compound extract on the expression of VEGFR1 in the scar tissue of the rat tail

[0079] Note: Compared with the Control group, # P<0.05, ## P<0.01; compared with the Model group, * P<0.05, ** P<0.01.

[0080] 3.5.8 Effect of the compound extract on the expression of COLⅢ in the tail scar tissue of experimental rats Compared with the blank group, the expression of COLⅢ protein in the model group was significantly increased, and the expression was significantly reduced after administration, and the expression was significantly reduced at low, medium and high doses ( P <0.05), the results are shown in the table below.

[0081] Table 12. Effect of compound extract on COLⅢ expression in rat tail scar tissue

[0082] Note: Compared with the Control group, # P <0.05, ## P <0.01; compared with the Model group, * P <0.05, ** P <0.01.

[0083] The results of the study showed that the compound extract inhibited VEGFR1 activity through the JAK2 / STAT3 signaling pathway, thereby reducing angiogenesis and playing a role in scar repair, thereby effectively removing scars formed by tissue hyperplasia without side effects and good safety. It can be seen that the present invention provides an effective technical means for the treatment of scars.

[0084] The above embodiments describe the preferred implementation of the present invention, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A composite extract for treating scars, characterized in that: The composite extract is prepared by mixing a scopolamine leaf extract and a panax notoginseng extract; the scopolamine leaf extract is prepared by mixing and crushing scopolamine leaves and gallstones, adding an ammonia ethanol solution for extraction, then adding vegetable oil for heating and mixing, volatilizing to remove ammonia, filtering to remove the filter residue, and collecting the oily extract to obtain the scopolamine leaf extract; the panax notoginseng extract is prepared by crushing the panax notoginseng, adding water for decoction, and then concentrating and drying to obtain a powder.

2. The composite extract for treating scars according to claim 1, characterized in that: By weight, when preparing the Scopolamine leaf extract, the Scopolamine leaf is 8-12 parts and the gallstones are 3-9 parts; when preparing the Panax japonicus extract, the Panax japonicus is 6-10 parts.

3. The composite extract for treating scars according to claim 1, characterized in that: The ammonia ethanol solution is an ethanol solution with a volume percentage of ammonia of 20%; the amount of the ammonia ethanol solution added is 0.8 to 1.2 times the total mass of scopolamine leaves and gallstones; the extraction time is 18 to 30 hours.

4. The composite extract for treating scars according to claim 1, characterized in that: The vegetable oil is peanut oil, and the added amount is 8 to 12 times the sum of the mass of scopolamine leaves and gallstones; the heating temperature is 60 to 70°C.

5. The composite extract for treating scars according to claim 1, characterized in that: When preparing the Panax japonicus extract, the extract is boiled and extracted for multiple times with water, the boiled extracts are combined and concentrated under reduced pressure, and finally spray-dried to obtain the extract.

6. Use of the composite extract according to any one of claims 1 to 5 in the preparation of scar removing drugs.

7. A drug for removing scars, characterized in that: The active ingredient of the medicine is the composite extract according to any one of claims 1 to 5.

8. The drug according to claim 7, characterized in that: The drug also includes pharmaceutically acceptable excipients.

9. The drug according to claim 7, characterized in that: Its dosage form is cream, ointment, gel, liniment or patch.

Images